Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102, for the management of fibromyalgia syndrome and TNX-105 to treat symptoms of post-traumatic stress disorder. Tonix Pharmaceuticals Holding Corp. is headquartered in New York.
Revenue (Most Recent Fiscal Year) | $7.77M |
Net Income (Most Recent Fiscal Year) | $-116.66M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.09 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -1501.78% |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -87.67% |
Return on Assets (Trailing 12 Months) | -73.77% |
Current Ratio (Most Recent Fiscal Quarter) | 2.53 |
Quick Ratio (Most Recent Fiscal Quarter) | 1.81 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.06 |
Inventory Turnover (Trailing 12 Months) | 0.47 |
Book Value per Share (Most Recent Fiscal Quarter) | $1.80 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.86 |
Earnings per Share (Most Recent Fiscal Year) | $-6.85 |
Diluted Earnings per Share (Trailing 12 Months) | $-8.62 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 84.49M |
Free Float | 84.10M |
Market Capitalization | $13.25M |
Average Volume (Last 20 Days) | 4.16M |
Beta (Past 60 Months) | 2.21 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 0.46% |
Percentage Held By Institutions (Latest 13F Reports) | 82.26% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |